The TMEM106B locus and TDP-43 pathology in older persons without FTLD

Neurology

Volumn 84, Issue 9, 2015, Pages 927-934

  Yu, Lei ^a,b   De Jager, Philip L ^c,d,e   Yang, Jingyun ^a,b   Trojanowski, John Q ^f   Bennett, David A ^a,b   Schneider, Julie A ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; TRANSMEMBRANE PROTEIN 106B; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NERVE PROTEIN; TMEM106B PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DEGENERATIVE DISEASE; DNA METHYLATION; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; HIPPOCAMPAL SCLEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TDP 43 PROTEINOPATHY; AGED; AGING; GENETICS; PATHOLOGY; TDP-43 PROTEINOPATHIES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENETIC LOCI; HUMANS; MALE; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TDP-43 PROTEINOPATHIES;

EID: 84924217131     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001313     Document Type: Article

References (34)

1. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.
2. Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007;61:435-445.
3. Nakashima-Yasuda H, Uryu K, Robinson J, et al. Comorbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 2007;114:221-229.
4. Nelson PT, Smith CD, Abner EL, et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol 2013;126:161-177.
5. Zarow C, Weiner MW, Ellis WG, Chui HC. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav 2012;2:435-442.
6. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234-239.
7. van der Zee J, Van Langenhove T, Kleinberger G, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 2011;134:808-815.
8. Kovacs GG, Alafuzoff I, Al-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 2008; 26:343-350.
9. Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009;5:649-658.
10. Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of lateonset amnestic dementias. Acta Neuropathol 2014;128:411-421.
11. Rutherford NJ, Carrasquillo MM, Li M, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 2012;79:717-718.
12. Nicholson AM, Finch NA, Wojtas A, et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 2013;126:781-791.
13. Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2011;76:467-474.
14. Cruchaga C, Graff C, Chiang HH, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 2011;68:581-586.
15. Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 2012;287:19355-19365.
16. Chen-Plotkin AS, Unger TL, Gallagher MD, et al. TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 2012;32:11213-11227.
17. Banzhaf-Strathmann J, Claus R, Mücke O, et al. Promoter DNA methylation regulates progranulin expression and is altered in FTLD. Acta Neuropathol Commun 2013;1:16.
18. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012;9:630-647.
19. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012;9:648-665.
20. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. Stroke 2005;36:954-959.
21. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer's disease pathology. Neurology 2004;62:1148-1156.
22. Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135:3005-3014.
23. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5-22.
24. Shulman JM, Yu L, Buchman AS, et al. Association of Parkinson disease risk loci with mild parkinsonian signs in older persons. JAMA Neurol 2014;71:429-435.
25. Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. Biochem Pharmacol 2014;88:617-630.
26. De Jager PL, Srivastava G, Lunnon K, et al. Alzheimer's disease pathology is associated with early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat NeuroSci 2014;17:1156-1163.
27. Wong HK, Veremeyko T, Patel N, et al. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum Mol Genet 2013;22:3077-3092.
28. Hébert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer 's disease, dementia with Lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis 2013;35:335-348.
29. Wilson RS, Yu L, Trojanowski JQ, et al. TDP-43 pathology, cognitive decline, and dementia in Old age. JAMA Neurol 2013;70:1418-1424.
30. Keage HA, Hunter S, Matthews FE, et al. TDP-43 in the population: prevalence and associations with dementia and age. J Alzheimers Dis Epub 2014 Jun 13.
31. Nelson PT, Estus S, Abner EL, et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014;127:825-843.
32. Van Damme P, Van Hoecke A, Lambrechts D, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 2008;181:37-41.
33. Malaspina A, Kaushik N, de Belleroche J. Differential expression 14 genes amyotrophic lateral sclerosis spinal cord detected using gridded CDNA arrays. J Neurochem 2001;77:132-145.
34. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;4:7.